Physician profile
Alla A Bodner
NPI 1669723573
$3,850.14
in general payments reported to CMS, 2019-2025
36 companies · $415 in 2025
The $415 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $447 · 2021: $780 · 2022: $1,153 · 2023: $436 · 2024: $351 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $499.36 | 2019-2023 | Lo Loestrin Fe |
| Novo Nordisk INC | $348.63 | 2019-2025 | Wegovy |
| Exeltis, USA INC. | $322.32 | 2019-2025 | Solosec, Slynd |
| Mayne Pharma Commercial LLC | $297.63 | 2021-2025 | |
| Hologic Sales and Service, LLC | $214.46 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Coopersurgical, INC. | $212.94 | 2019-2025 | Fisherbrand Disposable Liquid Infant Heel Warmer, Paragard T 380a, Summit Doppler |
| Organon LLC | $195.72 | 2021-2024 | Nexplanon |
| Gynesonics, INC. | $194.63 | 2022 | |
| Therapeuticsmd, INC. | $179.23 | 2020-2022 | |
| Pfizer INC. | $158.87 | 2020-2023 | |
| Myovant Sciences INC. | $128.12 | 2022 | |
| Avion Pharmaceuticals | $110.52 | 2021-2022 | |
| Lupin INC. | $109.84 | 2020 | |
| Aspira Women'S Health INC | $100.02 | 2021-2024 | Ova1 |
| Merck Sharp & Dohme LLC | $99.66 | 2019-2024 | Gardasil, Gardasil 9 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $87.89 | 2021-2023 | Twirla |
| Shield Therapeutics INC | $82.07 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $81.88 | 2023-2025 | Myfembree |
| Currax Pharmaceuticals LLC | $72.13 | 2022-2023 | Contrave, Onzetra Xsail, Nexlizet |
| Biogen, INC. | $55.35 | 2025 | Zurzuvae |
| Monaghan Medical Corporation | $32.83 | 2023-2024 | Aerobika, Aeroeclipse |
| Arjo INC. | $26.82 | 2025 | |
| Axsome Therapeutics, INC. | $26.27 | 2023 | Auvelity |
| Channel Medsystems, INC. | $25.24 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $24.57 | 2023 | Exparel |
| Mylan Pharmaceuticals INC. | $21.46 | 2021 | |
| Vertical Pharmaceuticals, LLC | $18.76 | 2020 | |
| Millicent US INC | $17.62 | 2025 | Femlyv, Intrarosa |
| Daiichi Sankyo INC. | $17.38 | 2021 | |
| Medicem INC. | $16.11 | 2020 | |
| Northgate Technologies, INC. | $15.94 | 2024 | Stimsite |
| Evofem Biosciences, INC. | $15.93 | 2021 | |
| Smith+Nephew, INC. | $14.45 | 2025 | Stravix Pl |
| Dysis Medical, INC. | $12.98 | 2019 | |
| Zyla Life Sciences, INC. | $12.51 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Bodner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.